Quark Venture is a Canadian-based venture capital investment firm. Established in 2015, Quark Venture is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.
Our strategic goal is to support and enable companies we invest in to grow, create value and be successful by providing not only financial support, but also developmental, infrastructure and expertise support, as needed, through our global network.
Our approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology. This approach has previously been successfully demonstrated in the energy and high-tech sectors where Quark Venture partners have invested.
While Quark Venture is headquartered in Vancouver, it has offices in Boston, Hong Kong and Chengdu, and plans to establish a European office in 2017.
Quark Venture is led by a unique senior management team and supported by a scientific and commercial advisory board. Quark Venture’s senior management team has both broad and deep expertise in finance, commercialization, venture, science, biotechnology, innovation, translation, strategic alliances, leadership and management.
Quark Venture has jointly established a new US$500 million Global Health Sciences Venture Fund. Quark Venture Inc. and GF Securities Company Limited, a leading investment bank in China, have jointly established a new US$500 million global health sciences venture fund to be based in Vancouver. The fund will invest globally in a diversified portfolio of innovative biotechnology and health sciences companies who are addressing unmet medical needs through innovations in drug development, medical devices, health IT and emerging convergent technologies.
This partnership capitalizes on our strong, experienced, globally connected team with its track-record in technology sourcing, screening and commercialization, as well as on GF Securities’ integrated strengths in investment, capital solutions, biotechnology IPO listing and expertise in China’s biomedical industry. Other lead fund investors include Chinese private and public investment banks and large publicly traded companies.